Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2214
Gene Symbol: FCGR3A
FCGR3A 		0.030 Biomarker disease BEFREE FCGR3A 158V/V and presentation with LON were associated with a longer flare-free survival (p = 0.023 and p = 0.031, respectively). 28270182 2017
Entrez Id: 2214
Gene Symbol: FCGR3A
FCGR3A 		0.030 GeneticVariation disease BEFREE The FCGR3A-158V/V genotype was associated with LON compared with V/F (P = 0.028) and F/F genotypes (P = 0.005). 21883784 2012
Entrez Id: 2214
Gene Symbol: FCGR3A
FCGR3A 		0.030 Biomarker disease BEFREE Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism. 20730791 2010
Entrez Id: 10673
Gene Symbol: TNFSF13B
TNFSF13B 		0.020 AlteredExpression disease BEFREE BAFF levels increased from baseline (median: 0.62 ng/ml) to the post-treatment evaluation (median: 1.16 ng/ml; p < 0.001); post-treatment levels were higher in the LON group ( p = 0.021). 29783918 2018
Entrez Id: 10673
Gene Symbol: TNFSF13B
TNFSF13B 		0.020 GeneticVariation disease BEFREE In this study, we aimed to investigate the role of established Fcγ receptor gene (FCGR) polymorphisms and B-cell-activating factor (BAFF) gene promoter polymorphisms for the development of LON and for the efficacy of rituximab in patients with rheumatic diseases. 28270182 2017
Entrez Id: 1440
Gene Symbol: CSF3
CSF3 		0.010 Biomarker disease BEFREE Late-onset neutropenia (LON) requiring granulocyte colony-stimulating factor occurred more frequently in the ABOi group than in the ABOc group (4 vs. 0 patients) (P < 0.001). 31673829 2020
Entrez Id: 10541
Gene Symbol: ANP32B
ANP32B 		0.010 Biomarker disease BEFREE Distinct roles of BAFF and APRIL are implicated: BAFF may contribute to LON development, whereas high APRIL levels may be predictive. 29783918 2018
Entrez Id: 3569
Gene Symbol: IL6
IL6 		0.010 AlteredExpression disease BEFREE IL-6 and GM-CSF levels decreased in the non-LON group ( p < 0.001), but not in LON patients. 29783918 2018
Entrez Id: 1437
Gene Symbol: CSF2
CSF2 		0.010 AlteredExpression disease BEFREE IL-6 and GM-CSF levels decreased in the non-LON group ( p < 0.001), but not in LON patients. 29783918 2018
Entrez Id: 8741
Gene Symbol: TNFSF13
TNFSF13 		0.010 Biomarker disease BEFREE Distinct roles of BAFF and APRIL are implicated: BAFF may contribute to LON development, whereas high APRIL levels may be predictive. 29783918 2018
Entrez Id: 1649
Gene Symbol: DDIT3
DDIT3 		0.010 Biomarker disease BEFREE Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma. 21883784 2012
Entrez Id: 712
Gene Symbol: C1QA
C1QA 		0.010 GeneticVariation disease BEFREE The FCGR3A-V158F but not the C1qA-A276G polymorphism influenced the risk of developing LON. 21883784 2012